MBX
Income statement / Annual
Last year (2024), MBX Biosciences, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, MBX Biosciences, Inc. Common Stock's net income was -$61.92 M.
See MBX Biosciences, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$57.42 M
|
$28.53 M
|
$21.40 M
|
| General & Administrative Expenses |
$10.78 M
|
$6.78 M
|
$3.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.78 M
|
$6.78 M
|
$3.76 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$68.19 M
|
$35.31 M
|
$25.16 M
|
| Cost And Expenses |
$68.19 M
|
$35.31 M
|
$25.16 M
|
| Interest Income |
$6.27 M
|
$2.75 M
|
$372.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$374.00 K
|
| Depreciation & Amortization |
$244.00 K
|
$157.00 K
|
$56.00 K
|
| EBITDA |
-$67.95 M |
-$35.15 M |
-$25.71 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.27 M
|
$2.75 M
|
-$974.00 K
|
| Income Before Tax |
-$61.92 M
|
-$32.56 M
|
-$26.14 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$61.92 M
|
-$32.56 M
|
-$26.14 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-1.85 |
-1.02 |
-0.82 |
| EPS Diluted |
-1.85 |
-1.02 |
-0.82 |
| Weighted Average Shares Out |
$33.39 M
|
$31.85 M
|
$31.85 M
|
| Weighted Average Shares Out Diluted |
$33.39 M
|
$31.85 M
|
$31.85 M
|
| Link |
|
|
|
